Journal
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS
Volume 31, Issue 4, Pages 399-404Publisher
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/COC.0b013e31815e456d
Keywords
bacteriocin; antimicrobial peptide; cancer; prevention
Categories
Ask authors/readers for more resources
Bacteriocins are antimicrobial peptides produced by a wide range of bacteria. Their antineoplastic properties have been inadequately revealed in the late 70s by Using Crude bacteriocin preparation toxic to mammalian cells. Nowadays, purified bacteriocins are available and have shown inhibitory properties toward diverse neoplastic line cells. Pyocin, colicin, pediocin, and microcin are among bacteriocins reported to present such activity. Moreover, modified bacteriocins proved to be effective in a glioblastoma xenograft mouse model. Screening for the presence of bacteriocin in colon cancer subjects has been studied with mixed results. Bacteriocin use as a therapeutic agent or in a prevention setting is discussed specifically evaluating bacteriocins biochemical properties and recent advances in peptide therapeutics.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available